Development and characterization of monoclonal antibodies specific for amylin.
Development and characterization of monoclonal antibodies specific for amylin.
复制标题
胰淀素特异性单克隆抗体的开发和表征。
作者：
Phelps,JL;Blase,EK;Koda,JE
高选择性单克隆抗体的肽激素人胰淀素已经产生和表征。这些抗体是由BALB/c来源的骨髓瘤和近交系或远交系小鼠的脾细胞融合产生的杂交瘤产生的。这些抗体的某些识别表位在氨基端或修饰的羧基端，以及37个氨基酸肽的中心区域的构象表位。其中一些抗体与降钙素和降钙素基因相关肽（CGRP）等相关肽激素的交叉反应性低于0.1%，并在低纳摩尔范围内具有明显的亲和力。选择抗体对用于直接测量内源性amylin和合成的人amylin类似物pramlintide（25,28,29三亲人amylin）的双位点测定，pramlintide目前正在临床研究中，用于改善胰岛素治疗的I型和II型糖尿病患者的血糖控制。
Highly selective monoclonal antibodies to the peptide hormone human amylin have been produced and characterized. These antibodies are produced by hybridomas resulting from the fusions of BALB/c-derived myelomas and splenocytes from either inbred or outbred mouse strains. Certain of these antibodies recognize epitopes at the amino-terminus or the amidated carboxy-terminus, as well as conformational epitopes within the central region of the 37 amino acid peptide. Several of these antibodies show less than 0.1% cross-reactivity with related peptide hormones such as calcitonin and calcitonin gene-related peptide (CGRP) and have apparent affinities in the low nanomolar range. Antibody pairs were selected for use in two-site assays for the direct measurement of endogenous amylin and the synthetic human amylin analogue, pramlintide (25, 28, 29 tripro-human amylin), which is presently under clinical investigation for improving glucose control in patients with both Type I and Type II diabetes treated with insulin.